Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)
Spastic paraplegia type 50 (SPG50) is an extremely rare inherited condition that causes progressive muscle weakness, stiffness in the legs, and learning difficulties in children. This clinical trial is testing an experimental gene therapy called Melpida. Melpida is designed to deliver a working copy of the faulty gene directly into the spinal fluid through a small injection in the lower back (a lumbar puncture). Before and after the treatment, participants receive medicines such as steroids to help calm the immune system and protect against side effects. Doctors will follow participants closely for three years (156 weeks). They will measure improvements in key movement milestones—such as sitting, crawling, or walking—as well as speech, learning, and overall quality of life. The aim is to confirm whether Melpida can slow down, stop, or even improve the symptoms of SPG50.
Överblick
Vad handlar denna studie om?
Hereditary spastic paraplegia type 50, often shortened to SPG50, is an ultra-rare genetic disease that begins in early childhood. Children with SPG50 have a change in a specific gene that their brain and nerve cells need to communicate properly. Over time, this leads to stiff muscles, trouble walking, speech difficulties, and delays in intellectual development. Currently, there is no cure, and treatments only manage day-to-day symptoms.
This phase 3 study is evaluating Melpida, a gene therapy created to tackle the root cause of SPG50. Melpida carries a healthy version of the missing gene to nerve cells. It is given as a single injection into the spinal fluid around the spinal cord, allowing it to reach the central nervous system directly.
Because this is a phase 3 trial, researchers want to gather solid evidence showing whether Melpida is safe and effective. They will compare children who receive the gene therapy against a group of patients followed over the same period without the new therapy. Finding a treatment that halts or reverses SPG50 could dramatically improve independence and long-term quality of life for children living with this condition.
Viktiga punkter
- Tests Melpida, an experimental single-dose gene therapy for hereditary spastic paraplegia type 50 (SPG50).
- Aimed at improving or protecting motor skills, movement, and cognitive development.
- Delivered via an injection into the spinal fluid alongside temporary immune-calming medicines.
- Follows participants over three years (156 weeks) to track development and safety.
- Open to people diagnosed with SPG50 across all age groups.
Vem kan vara berättigad?
This trial is open to people of any age who have a confirmed genetic diagnosis of hereditary spastic paraplegia type 50 (SPG50). Both males and females can take part.
Because gene therapy requires a general anaesthetic and a procedure to inject the medicine into the spine, participants must be well enough to safely undergo these steps. The study team will review medical records and run baseline health tests to make sure the treatment is suitable.
People who have other serious medical conditions that might make spinal injections or immune-suppressing medicines unsafe may not be able to participate. Your specialist doctor or the trial team can confirm whether this study is an appropriate option.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Has a confirmed genetic diagnosis of hereditary spastic paraplegia type 50 (SPG50)
- Is well enough to undergo a lumbar puncture and general anaesthetic if required
- Is able to take temporary medicines that calm the immune system
- Can travel to the study clinic for regular appointments and developmental checks over three years
Vad innebär deltagande?
Taking part in this study lasts for about three years (156 weeks). At the start, participants have detailed health checks, including blood tests, physical exams, and an MRI scan using a special dye to look at the brain and spine.
Participants then receive Melpida as a single injection into the fluid around the spine. Around the time of treatment, they will also take standard medicines—such as paracetamol, antihistamines, and steroids—to stop the body's immune system from reacting against the therapy.
After the injection, there will be regular hospital visits. The medical team will check walking, muscle stiffness, and developmental progress through simple tasks, play-based tests, and blood samples. Parents and carers will also fill in questionnaires about everyday abilities and overall well-being.
Potentiella risker och fördelar
Platser (1)
- —ObekräftadSpanien
Vanliga frågor
What is Melpida and how does it work?
Melpida is an experimental gene therapy. It carries a healthy copy of the gene that is faulty in SPG50, helping nerve cells make the protein they need to work properly.
Hur ges behandlingen?
It is given once through a lumbar puncture, which is a small injection into the fluid surrounding the spinal cord in the lower back, usually under sedation or anaesthetic.
Why are medicines like steroids and paracetamol used?
These medicines help calm the immune system so it does not attack the new gene therapy, keeping the treatment safe and helping it work as intended.
How long will my child need to be monitored?
The trial monitors participants for 156 weeks (about three years) to carefully check both short-term safety and long-term improvements in movement and learning.
Does taking part mean we cannot change our minds?
No. Taking part is entirely your choice. You can decide to leave the trial at any point, and your child's standard medical care will not be affected.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.